Therakind (Jylamvo Drug) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Therakind (Jylamvo Drug) General Information

Description

Oncology and autoimmune drug intended to serve individuals across US market. The asset is a sweet tasting oral methotrexate solution that eliminates the need for crushing or splitting pills, or compounding into a liquid formulation.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • London
  • England, United Kingdom
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Shorla Oncology
Corporate Office
  • London
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Therakind (Jylamvo Drug) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Therakind (Jylamvo Drug)‘s full profile, request access.

Request a free trial

Therakind (Jylamvo Drug) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Therakind (Jylamvo Drug)‘s full profile, request access.

Request a free trial

Therakind (Jylamvo Drug) FAQs

  • Where is Therakind (Jylamvo Drug) headquartered?

    Therakind (Jylamvo Drug) is headquartered in London, United Kingdom.

  • What industry is Therakind (Jylamvo Drug) in?

    Therakind (Jylamvo Drug)’s primary industry is Buildings and Property.

  • Is Therakind (Jylamvo Drug) a private or public company?

    Therakind (Jylamvo Drug) is a Private company.

  • What is Therakind (Jylamvo Drug)’s current revenue?

    The current revenue for Therakind (Jylamvo Drug) is .

  • Who are Therakind (Jylamvo Drug)’s investors?

    Therakind has invested in Therakind (Jylamvo Drug).

  • When was Therakind (Jylamvo Drug) acquired?

    Therakind (Jylamvo Drug) was acquired on 31-Oct-2023.

  • Who acquired Therakind (Jylamvo Drug)?

    Therakind (Jylamvo Drug) was acquired by Shorla Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process